» Articles » PMID: 36503476

Human Monkeypox: a Comparison of the Characteristics of the New Epidemic to the Endemic Disease

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2022 Dec 12
PMID 36503476
Authors
Affiliations
Soon will be listed here.
Abstract

In May 2022, a new global outbreak of mpox (formerly, human monkeypox) emerged that was declared a public health emergency of international concern by the World Health Organization on July 23, 2022. With new patterns of person-to-person spread within sexual networks in nonendemic countries and several differences from the classic disease course, we performed a comprehensive review of existing literature on human monkeypox to discuss epidemiology, modes of transmission, clinical presentation and asymptomatic infection, diagnostics, therapeutics, and vaccines with the primary aim to identify important areas for future research of this new epidemic form of the disease. A comprehensive literature search was performed of all published literature to August 15, 2022. Historically, in regions of monkeypox virus endemicity, human outbreaks have occurred related to discrete zoonotic events. The animal reservoir is unknown, but the virus has been isolated from rodents. Traditionally, transmission occurred by direct or indirect contact with an infected animal. In nonendemic countries affected in the 2022 outbreak, almost exclusive person-to-person spread has been observed, and most cases are connected to sexual networks of gay, bisexual, and other men who have sex with men. After an incubation period of approximately 13 days, in traditional human cases affected persons developed a febrile prodrome preceding a rash that started on the face and body, spread centrifugally to the palms and soles and healed monomorphically over two to four weeks. However, in the 2022 outbreak, the febrile illness is often absent or occurs after the onset of the rash. The rash presents primarily in the anogenital region and face before disseminating throughout the body, with lesions displaying regional pleomorphism. There is a paucity of data for the role of antiviral agents or vaccines. The epidemiology and clinical course of mpox has changed in the 2022 epidemic from that observed with the endemic disease. There is an urgent need to establish rapid and collaborative research platforms to diagnose, treat and prevent disease and inform important public health and other strategies to stop the spread of disease.

Citing Articles

Clade Ib: a new emerging threat in the Mpox outbreak.

Srivastava S, Laxmi , Sharma K, Sridhar S, Talath S, Shareef J Front Pharmacol. 2025; 15:1504154.

PMID: 39749207 PMC: 11693458. DOI: 10.3389/fphar.2024.1504154.


An Epidemiological and Clinical Study of Monkeypox in Changsha, China: A Retrospective Analysis of HIV-Infected and Non-HIV-Infected Patients from June to December 2023.

Li J, Yuan X, Peng J, Hou X, Zheng F, Xiao G Infect Drug Resist. 2024; 17:5305-5313.

PMID: 39628830 PMC: 11614583. DOI: 10.2147/IDR.S485232.


A Cross-Sectional Evaluation of the Virtual Outpatient Management of People With Mpox.

Warrell C, Chaudhry Z, Shawe-Taylor M, Mastoraki E, Delmonte Sen A, Rafferty H Open Forum Infect Dis. 2024; 11(8):ofae413.

PMID: 39113827 PMC: 11304594. DOI: 10.1093/ofid/ofae413.


Effectiveness and Safety of the MVA-BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc).

Back S, Knox B, Coakley C, Deltour N, Jacquot E, Raad H Vaccines (Basel). 2024; 12(6).

PMID: 38932380 PMC: 11209565. DOI: 10.3390/vaccines12060651.


Mpox in children and adolescents and contact follow-up in school settings in greater Paris, France, May 2022 to July 2023.

Reques L, Mercuriali L, Silue Y, Chazelle E, Spaccaferri G, Velter A Euro Surveill. 2024; 29(21).

PMID: 38785093 PMC: 11128737. DOI: 10.2807/1560-7917.ES.2024.29.21.2300555.


References
1.
Thornhill J, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison L . Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med. 2022; 387(8):679-691. DOI: 10.1056/NEJMoa2207323. View

2.
Nakazawa Y, Emerson G, Carroll D, Zhao H, Li Y, Reynolds M . Phylogenetic and ecologic perspectives of a monkeypox outbreak, southern Sudan, 2005. Emerg Infect Dis. 2013; 19(2):237-45. PMC: 3559062. DOI: 10.3201/eid1902.121220. View

3.
Fleischauer A, Kile J, Davidson M, Fischer M, Karem K, Teclaw R . Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis. 2005; 40(5):689-94. DOI: 10.1086/427805. View

4.
Buller R, Owens G, Schriewer J, Melman L, Beadle J, Hostetler K . Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology. 2004; 318(2):474-81. DOI: 10.1016/j.virol.2003.11.015. View

5.
P Monath T, Caldwell J, Mundt W, Fusco J, Johnson C, Buller M . ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. Int J Infect Dis. 2004; 8 Suppl 2:S31-44. PMC: 7110559. DOI: 10.1016/j.ijid.2004.09.002. View